BHVN at a glance
Biohaven Ltd. (BHVN, SEC CIK 1935979) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Biohaven Ltd. (BHVN) shares worth $620.3 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 28 funds
- $620.3M · −1 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Biopharmaceutical development focused on neurological therapies, notably troriluzole
- New financing structure: $250M initial senior secured notes plus up to $350M contingent tranches linked to regulatory approvals
- Strategic shift to revenue-based funding with royalty-like payments of 6.25%+ on global net sales of troriluzole
- Most notable metric: $250 million proceeds received from First Notes in April 2025 under Note Purchase Agreement
- Unique feature: Complex milestone, revenue payment caps, and call/put options tied to FDA/EMA approval timelines and sales benchmarks
Risk Factors
- Key regulatory risk: FDA approval dependency for troriluzole to unlock $150M senior secured notes tranche under April 2025 Note Purchase Agreement
- Geopolitical/macro threat: Tax provision exposure from profitable US and Ireland subsidiaries, with net deferred tax assets fully reserved against realization
- Operational risk: One-time $42.7M cash milestone payment to Knopp in January 2026 related to 2025 Additional Consideration under Knopp Amendment
- Competitive risk: Royalty buyback of $867.5M milestone payments to Knopp reduces future payments but exposes to mid-single digit flat royalty on Kv7 programs
- Financial risk: Liquidity pressure with net operating loss and $609.4M cash used in operations in 2025 despite $230M cash and $89.2M marketable securities on hand
Management Discussion & Analysis
- No management outlook, guidance, or key emerging risks mentioned
- Text focuses on industry data sources, estimates, and trademark notices
AI summary of the BHVN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY, with no product sales
- Net loss $129.3M vs $173.4M YoY, operating margin not meaningful due to no revenue
- Highest R&D spend: BHV-1400 at $10.1M, lowest: BHV-2100 and BHV-2110 at $(1.2)M
- Cash and equivalents $95.8M plus marketable securities $65.4M; operating cash use $341.9M year-to-date
- Outlook: RISE 3 topline results on track for second half of 2026; BHV-7000 enrollment paused under partial clinical hold
Risk Factors
- New Ono collaboration risk: October 2026 license covers MoDE™ degraders in Japan, South Korea, Taiwan, and ASEAN
- Most materially updated financial risk: no committed external funding beyond potential SKBP and Ono payments
- Regulatory and compliance risk: SKBP HSR waiting period expired October 28, 2026, but remaining closing conditions persist
- Operational risk: SKBP controls development resources for Kv7 products, including opakalim
- Financial risk: SKBP agreement includes $400.0 million upfront and up to $150.0 million milestone payments at risk
AI summary of the BHVN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Investor presentation at Jefferies Global Healthcare Conference, London, November 16-19
- Exhibit 99.1 contains Biohaven’s conference materials, potentially relevant for pipeline and corporate updates
Item EX-99.1: Item EX-99.1
- November 2026 corporate presentation highlights Biohaven’s protein-degrader platform and broad pipeline across autoimmune disease, epilepsy, pain, oncology, and neurology
- BHV-1300 Graves’ disease Phase 3 initiated, following preliminary data showing over 80% TSHR autoantibody reduction and hormone normalization within 3 to 5 weeks
Item EX-99.1: Item EX-99.1
- FDA accepted Vyglxia NDA resubmission for SCA, with advisory committee review and user-fee goal date in 1Q27
- Ono license provides $80M upfront, up to $20M milestone, and approximately 20% royalties while preserving US, Europe, and China rights
Item 2.02: Results of Operations and Financial Condition
- Biohaven reported third-quarter financial results for the period ended September 30, 2026
- Investor-relevant revenue, earnings and cash-flow details are in Exhibit 99.1, the accompanying earnings release
Item 7.01: Regulation FD Disclosure
- FDA accepted Vyglxia resubmission for SCA review, signaling the application cleared completeness requirements
- First-quarter 2027 user fee goal date, establishing the next major regulatory catalyst
AI summaries of BHVN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BHVN
Don't miss the next BHVN filing
- Alerts as it files. A push when BHVN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BHVN, by share count.
- Ask anything. An AI agent that reads every BHVN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Gentile Kimberly | A | Sep 15, 2026 | 1,000 | - |
| HUGIN ROBERT J | A | Apr 28, 2026 | 68,693 | - |
| Heffernan Michael Thomas | A | Apr 28, 2026 | 68,693 | - |
| Bailey Gregory | A | Apr 28, 2026 | 68,693 | - |
| Mehta Kishan | A | Apr 28, 2026 | 68,693 | - |
| CHILDS JOHN W | A | Apr 28, 2026 | 68,693 | - |
| GREGORY JULIA P | A | Apr 28, 2026 | 68,693 | - |
| Antonijevic Irina | A | Apr 28, 2026 | 68,693 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$436.1M | -$885.1M | -$745.4M |
| Net Income | -$408.2M | -$846.4M | -$738.8M |
| Balance Sheet | |||
| Total Assets | $513.2M | $615.1M | $451.4M |
| Equity | - | $423.4M | $52.1M |
| ROE | - | -199.9% | -1418.8% |
| Per Share | |||
| EPS | $-5.73 | $-9.28 | $-6.86 |
| Cash Flow | |||
| Operating CF | -$331.7M | -$582.5M | -$609.4M |
| CapEx | $3.0M | $4.0M | $715K |
Source: XBRL data in Biohaven Ltd. (BHVN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BHVN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $620.3M |
| Q2 2026 | 29 | $723.2M |
| Q1 2026 | 29 | $362.7M |
| Q4 2025 | 24 | $466.3M |
| Q3 2025 | 26 | $487.6M |
| Q2 2025 | 26 | $505.2M |
| Q1 2025 | 27 | $553.9M |
| Q4 2024 | 23 | $702.7M |
- Bank of America Corp+2.60M (+176%)
- Goldman Sachs Group+1.15M (+44%)
- Renaissance Technologies LLC+314.1K (+208%)
- JPMorgan Chase & Co+75.3K (+16%)
- Morgan Stanley+31.9K (+4%)
- D.E. Shaw & Co−465.0K (-11%)
- Millennium Management−380.8K (-91%)
- BlackRock−259.4K (-2%)
- Citigroup−236.3K (-75%)
- AQR Capital Management−97.4K (-2%)
- Bridgewater Associates LP+100.2K
- FMR LLC (Fidelity)−2.96M
- Citadel Advisors LLC−1.62M
Source: 13F-HR filings on SEC EDGAR (aggregated from 212 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BHVN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 22, 2026 | - | Analysis | - |
| 8-K | Oct 15, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 8-K | Jul 9, 2026 | - | Analysis | - |
| 8-K | May 27, 2026 | - | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 8-K | May 4, 2026 | - | - | - |
| 8-K | May 4, 2026 | - | Analysis | - |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BHVN SEC filings: frequently asked questions
Which institutions hold BHVN stock?
As of September 30, 2026, the largest Biohaven Ltd. (BHVN) holders among the 13F filers tracked by SignalX were BlackRock ($172.9 million), State Street Corp ($91.8 million), Bank of America Corp ($54.4 million), AQR Capital Management ($54.1 million), Goldman Sachs Group ($49.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in BHVN's latest 10-K?
In the 10-K filed March 2, 2026, Biohaven Ltd. (BHVN) flagged: Key regulatory risk: FDA approval dependency for troriluzole to unlock $150M senior secured notes tranche under April 2025 Note Purchase Agreement. Geopolitical/macro threat: Tax provision exposure from profitable US and Ireland subsidiaries, with net deferred tax assets fully reserved against realization. (AI summary of the Risk Factors section.)
What did BHVN report in its latest 8-K?
Biohaven Ltd. (BHVN) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Investor presentation at Jefferies Global Healthcare Conference, London, November 16-19.
What are the latest BHVN SEC filings?
Biohaven Ltd. (BHVN) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on September 17, 2026.
What is BHVN's SEC CIK number?
Biohaven Ltd. (BHVN)'s SEC Central Index Key (CIK) is 1935979. EDGAR lists every BHVN filing under that number.
Ask anything about BHVN
The research agent reads BHVN's filings, financials, insider trades and 13F holders, then answers with sources.